Isotropic Expansion of the Intraprostatic Gross Tumor Volume of Primary Prostate Cancer Patients Defined in MRI-A Correlation Study With Whole Mount Histopathological Information as Reference.
MRI
focal therapy for prostate
histopathologic comparison
prostate cancer
radiotherapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
20
08
2020
accepted:
28
10
2020
entrez:
17
12
2020
pubmed:
18
12
2020
medline:
18
12
2020
Statut:
epublish
Résumé
An accurate delineation of the intraprostatic gross tumor volume (GTV) is of importance for focal treatment in patients with primary prostate cancer (PCa). Multiparametric MRI (mpMRI) is the standard of care for lesion detection but has been shown to underestimate GTV. This study investigated how far the GTV has to be expanded in MRI in order to reach concordance with the histopathological reference and whether this strategy is practicable in clinical routine. Twenty-two patients with planned prostatectomy and preceded 3 Tesla mpMRI were prospectively examined. After surgery, PCa contours delineated on histopathological slides (GTV-Histo) were superimposed on MRI using In 19 of 22 patients MRI underestimated the intraprostatic tumor volume compared to histopathological reference: median GTV-Histo (4.7 cm Using histopathology as reference, we demonstrated that MRI underestimates intraprostatic tumor volume. A 2 mm-expansion may improve accurate GTV-delineation while respecting the balance between histological tumor coverage and overtreatment.
Identifiants
pubmed: 33330088
doi: 10.3389/fonc.2020.596756
pmc: PMC7719800
doi:
Types de publication
Journal Article
Langues
eng
Pagination
596756Informations de copyright
Copyright © 2020 Kramer, Spohn, Kiefer, Ceci, Sigle, Oerther, Schultze-Seemann, Gratzke, Bock, Bamberg, Grosu, Benndorf and Zamboglou.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):188-96
pubmed: 27375167
Radiat Oncol. 2018 May 2;13(1):81
pubmed: 29716617
Radiat Oncol. 2018 Apr 12;13(1):65
pubmed: 29650029
Eur Urol. 2014 Oct;66(4):732-51
pubmed: 23769825
Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):62-9
pubmed: 17707266
Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2796-2803
pubmed: 32342192
Radiother Oncol. 2015 May;115(2):186-90
pubmed: 25935742
Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1405-18
pubmed: 19616743
Eur Urol. 2019 May;75(5):712-720
pubmed: 30509763
JAMA. 1998 Sep 16;280(11):969-74
pubmed: 9749478
AJR Am J Roentgenol. 2014 Jan;202(1):109-20
pubmed: 24370135
Eur Urol. 2017 Apr;71(4):618-629
pubmed: 27568654
Radiother Oncol. 2013 Jun;107(3):274-81
pubmed: 23791306
Eur J Nucl Med Mol Imaging. 2016 May;43(5):889-897
pubmed: 26592938
Eur Urol. 2016 Jan;69(1):16-40
pubmed: 26427566
Theranostics. 2017 Jan 1;7(1):228-237
pubmed: 28042330
JAMA Oncol. 2018 Jun 14;4(6):e180039
pubmed: 29543933
Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):275-285
pubmed: 28262473
J Urol. 2006 Oct;176(4 Pt 1):1415-9
pubmed: 16952647
Diagn Interv Radiol. 2015 Sep-Oct;21(5):382-4
pubmed: 26200484
Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):438-45
pubmed: 25864171
J Urol. 2017 Feb;197(2):320-326
pubmed: 27484386
J Urol. 2001 Sep;166(3):876-81
pubmed: 11490237
N Engl J Med. 2018 May 10;378(19):1767-1777
pubmed: 29552975
Radiother Oncol. 2018 Apr;127(1):74-80
pubmed: 29336835
Trials. 2011 Dec 05;12:255
pubmed: 22141598
Radiother Oncol. 2019 Dec;141:208-213
pubmed: 31431386
Radiother Oncol. 2014 Feb;110(2):303-8
pubmed: 24444524
Radiother Oncol. 2019 Dec;141:214-219
pubmed: 31431366